Literature DB >> 22660443

Azole interactions with multidrug therapy in pediatric oncology.

Antonio Ruggiero1, Roberta Arena, Andrea Battista, Daniela Rizzo, Giorgio Attinà, Riccardo Riccardi.   

Abstract

Patients with cancer receive multidrug therapy. Antineoplastic agents and supportive care drugs are often administered together, leading to potential drug-drug interactions. These interactions may have significant clinical implications in terms of toxicity or a decrease in the efficacy of the treatment administered. Here, we focus on the role of azoles and their main pharmacokinetic interactions with the principal classes of drugs used in pediatric oncology. The co-administration of azoles and antineoplastic agents, corticosteroids, immunosuppressants, antacids, antiemetics, antiepileptic drugs and analgesics was investigated, and a practical guide on the management of these drugs when administered together is provided.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22660443     DOI: 10.1007/s00228-012-1310-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  71 in total

1.  Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.

Authors:  Toshiyuki Sakaeda; Koichi Iwaki; Mikio Kakumoto; Mika Nishikawa; Toshiro Niwa; Jiang-shu Jin; Tsutomu Nakamura; Kohshi Nishiguchi; Noboru Okamura; Katsuhiko Okumura
Journal:  J Pharm Pharmacol       Date:  2005-06       Impact factor: 3.765

Review 2.  Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.

Authors:  Zoe Dorothea Pana; Emmanuel Roilides
Journal:  Pediatr Blood Cancer       Date:  2011-01-24       Impact factor: 3.167

3.  The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

Authors:  J T Backman; K T Kivistö; K T Olkkola; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

4.  Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).

Authors:  I Buggia; M Zecca; E P Alessandrino; F Locatelli; G Rosti; A Bosi; A Pession; B Rotoli; I Majolino; A Dallorso; M B Regazzi
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

5.  Invasive fungal infections in pediatric oncology.

Authors:  Meirav Mor; Gil Gilad; Liora Kornreich; Salvador Fisher; Isaac Yaniv; Itzhak Levy
Journal:  Pediatr Blood Cancer       Date:  2011-02-11       Impact factor: 3.167

6.  Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.

Authors:  Alain J Romero; Patrick Le Pogamp; Lars-Goran Nilsson; Nolan Wood
Journal:  Clin Pharmacol Ther       Date:  2002-04       Impact factor: 6.875

7.  Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin.

Authors:  M P Ducharme; R L Slaughter; L H Warbasse; P H Chandrasekar; V Van de Velde; G Mannens; D J Edwards
Journal:  Clin Pharmacol Ther       Date:  1995-12       Impact factor: 6.875

8.  Voriconazole drastically increases exposure to oral oxycodone.

Authors:  Nora M Hagelberg; Tuija H Nieminen; Teijo I Saari; Mikko Neuvonen; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2008-10-03       Impact factor: 2.953

9.  Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Authors:  Thomas J Walsh; Mats O Karlsson; Timothy Driscoll; Adriano G Arguedas; Peter Adamson; Xavier Saez-Llorens; Ajay J Vora; Antonio C Arrieta; Jeffrey Blumer; Irja Lutsar; Peter Milligan; Nolan Wood
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 10.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

View more
  3 in total

1.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review.

Authors:  Yin Ting Cheung; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2015-04-07       Impact factor: 8.989

Review 2.  Neonatal pharmacology and clinical implications.

Authors:  Antonio Ruggiero; Anna Ariano; Silvia Triarico; Michele Antonio Capozza; Pietro Ferrara; Giorgio Attinà
Journal:  Drugs Context       Date:  2019-10-14

3.  Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment.

Authors:  Antonio Ruggiero; Daniela Rizzo; Martina Catalano; Paola Coccia; Silvia Triarico; Giorgio Attiná
Journal:  J Int Med Res       Date:  2018-04-24       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.